Lower-dose starting chemotherapy with G-CSF for children with acute myeloid leukemia
Tests lower-dose chemotherapy plus GCSF in children with acute myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients
Key facts
- Where
- Asyut, EgyptSee the site
Where in Egypt
- South Egypt Cancer Institute, Assiut UniveristyAsyut, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azza Shibl Sayed
- Trial code
- NCT07867600
- Record updated
- 9 October 2026
- Original description
the standard induction treatment for pediatric acute myeloid leukemia has high early morbidity and mortality that jeopardize the outcome especially in developing countries. SIOP recommended lower dose induction synergistic G- CSF to minimize these unwanted toxicities. the study aimed at minimizing the toxicities during induction without jeopardizing the survival.Read full original descriptionShow less
Outcome of Pediatric Patients With Acute Myeloid Leukemia Treated According to SIOP Guidelines in Developing Countries
the standard induction treatment for pediatric acute myeloid leukemia has high early morbidity and mortality that jeopardize the outcome especially in developing countries. SIOP recommended lower dose induction synergistic G- CSF to minimize these unwanted toxicities. the study aimed at minimizing the toxicities during induction without jeopardizing the survival.
Inclusion: Denovo pediatric AML patients; equal or <18 years old.
Exclusion: AML secondary to myelodysplastic syndrome or prior chemotherapy; Down syndrome with AML with age less than 4 years; Children with promyelocytic leukemia; death before treatment initiation.